Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
37 participants
INTERVENTIONAL
2015-10-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GLP-1 Infusion and Long-Time Fasting
NCT00285896
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
NCT06976619
Sustained Effects of a Non-glucidic Nutrient Preload on Glucose Tolerance in Type 2 Diabetes
NCT02477761
Effects of a Small Protein and Lipid Preload on Glucose Tolerance in Subjects With Impaired Glucose Homeostasis
NCT02342834
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
NCT01507597
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Prebiotic fibers: Oligofructose and inulin
Prebiotic fibers: oligofructose and inulin
Arm B
Maltodextrin
Maltodextrin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prebiotic fibers: oligofructose and inulin
Maltodextrin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 18,5 - 40
* Not medicated with insulin, GLP-1 analogues or DPP4 inhibitors
* Moderate intake of alcohol
* Not excessive exercise
* Less than 3 kg weight change the last two months
* Intake of less than 30 g dietary fiber per day
Exclusion Criteria
* IBS
* Coeliac disease
* Have used antibiotics within the last two months
* Have used supplements with prebiotics or probiotics the last two months
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Norwegian Diabetes Association
OTHER
Norwegian Extra Foundation for Health and Rehabilitation
OTHER
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anne-Marie Aas
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne-Marie Aas, PhD
Role: PRINCIPAL_INVESTIGATOR
Oslo University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oslo University Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Birkeland E, Bamigbetan WA, Molven KD, Thorsby PM, Gulseth HL, Aas AM, Dahl C. Can supplements with prebiotic fibres positively influence bone health in type 2 diabetes? Insights from a randomised controlled crossover trial. Arch Osteoporos. 2025 Jun 5;20(1):71. doi: 10.1007/s11657-025-01556-x.
Birkeland E, Gharagozlian S, Gulseth HL, Birkeland KI, Hartmann B, Holst JJ, Holst R, Aas AM. Effects of prebiotics on postprandial GLP-1, GLP-2 and glucose regulation in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled crossover trial. Diabet Med. 2021 Oct;38(10):e14657. doi: 10.1111/dme.14657. Epub 2021 Aug 7.
Birkeland E, Gharagozlian S, Birkeland KI, Valeur J, Mage I, Rud I, Aas AM. Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial. Eur J Nutr. 2020 Oct;59(7):3325-3338. doi: 10.1007/s00394-020-02282-5. Epub 2020 May 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1180 REK
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.